Recent bioequivalence studies on fixed-dose combination anti-tuberculosis drug formulations available on the global market
- PMID: 10593710
Recent bioequivalence studies on fixed-dose combination anti-tuberculosis drug formulations available on the global market
Abstract
Setting: Concern has been expressed about the bioavailability of rifampicin in some fixed-dose combination (FDC) anti-tuberculosis formulations.
Objective: To evaluate the relative bioavailability of rifampicin in various FDC formulations currently in use in tuberculosis control programmes in the global market.
Design: A two-period randomised crossover bioequivalence study in healthy male volunteers, with a 1 week washout period between treatments. Plasma rifampicin concentrations were measured at 0, 1, 2, 4, 6, 8 and 12 hours after each drug administration.
Results: The AUC0-8, AUC0-12 and Cmax for rifampicin in seven of 10 FDC formulations was not found to be bioequivalent to the reference administered as loose (separate) formulations. This was confirmed using parametric and non-parametric statistical methods.
Conclusions: The poor relative bioavailability of rifampicin from some FDCs has been documented. The implications for tuberculosis programmes are extremely serious and warrant urgent attention.
Similar articles
-
The potential use of urinary excretion data for assessing the relative bioavailability of rifampicin in fixed dose combination anti-tuberculosis formulations.Int J Tuberc Lung Dis. 2001 Aug;5(8):691-5. Int J Tuberc Lung Dis. 2001. PMID: 11495257 Clinical Trial.
-
Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels.Int J Pharm. 2004 May 19;276(1-2):41-9. doi: 10.1016/j.ijpharm.2004.02.019. Int J Pharm. 2004. PMID: 15113612 Clinical Trial.
-
Establishment of a reference formulation for bioequivalence assessment of rifampicin-containing FDCs: an essential step towards improving tuberculosis treatment.Int J Tuberc Lung Dis. 2005 Jul;9(7):791-6. Int J Tuberc Lung Dis. 2005. PMID: 16013776 Clinical Trial.
-
Rifampicin bioavailability: a review of its pharmacology and the chemotherapeutic necessity for ensuring optimal absorption.Int J Tuberc Lung Dis. 1999 Nov;3(11 Suppl 3):S301-8; discussion S317-21. Int J Tuberc Lung Dis. 1999. PMID: 10593709 Review.
-
Biopharmaceutic and pharmacokinetic aspects of variable bioavailability of rifampicin.Int J Pharm. 2004 Mar 1;271(1-2):1-4. doi: 10.1016/j.ijpharm.2003.11.031. Int J Pharm. 2004. PMID: 15129967 Review.
Cited by
-
Substandard/counterfeit antimicrobial drugs.Clin Microbiol Rev. 2015 Apr;28(2):443-64. doi: 10.1128/CMR.00072-14. Clin Microbiol Rev. 2015. PMID: 25788516 Free PMC article. Review.
-
Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring.Eur J Clin Pharmacol. 2016 Aug;72(8):905-16. doi: 10.1007/s00228-016-2083-4. Epub 2016 Jun 15. Eur J Clin Pharmacol. 2016. PMID: 27305904 Review.
-
Making up the difference: ensuring the bioequivalence of fixed-dose combinations for tuberculosis.Int J Tuberc Lung Dis. 2018 May 1;22(5):473-474. doi: 10.5588/ijtld.18.0210. Int J Tuberc Lung Dis. 2018. PMID: 29663947 Free PMC article. No abstract available.
-
Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana.Clin Infect Dis. 2009 Jun 15;48(12):1685-94. doi: 10.1086/599040. Clin Infect Dis. 2009. PMID: 19432554 Free PMC article.
-
Improved Stability of Rifampicin in the Presence of Gastric-Resistant Isoniazid Microspheres in Acidic Media.Pharmaceutics. 2020 Mar 5;12(3):234. doi: 10.3390/pharmaceutics12030234. Pharmaceutics. 2020. PMID: 32151053 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical